A Phase 3 interventional study of Dimethyl Fumarate and Peginterferon Beta-1a in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen. Terminated at 23 sites in 13 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-06-15.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 17th largest by enrollment, is the only one that started in 2019, is one of 10 in phase 3, and was the 22nd registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2019.
This study's enrollment of 11 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 53rd largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2019, is one of 25 in phase 3, and was the 69th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS. The other objectives of this study are to evaluate the safety and tolerability of dimethyl fumarate and peginterferon beta-1a and to assess the effect of dimethyl fumarate and peginterferon beta-1a, both compared with placebo, on additional clinical and radiological measures of disease activity.
Participants will be randomized in a 1:2:2 ratio to receive the double-blind study treatment (Dimethyl Fumarate, Peginterferon Beta-1a, and placebo). Participants experiencing a confirmed relapse or disability progression or high lesion burden on MRI will have the option to discontinue the blinded study treatment and switch to an alternative therapy or open-label BG00012.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).
Drug: Dimethyl Fumarate
Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).
Drug: Peginterferon Beta-1a
Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)
Drug: Placebo
Administered as specified in the treatment arm.
Also known as: Tecfidera, BG00012
Administered as specified in the treatment arm.
Also known as: Plegridy, BIIB017
Administered as specified in the treatment arm.
Time to First Relapse
A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. Time to relapse is defined as from the first dose of the study drug to the day of relapse. Time to First Relapse is estimated by Kaplan Mayer method.
Time frame: Baseline up to Week 96
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Baseline up to Week 100
Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 48 and 96
The number of new or newly enlarging T2 hyperintense lesions that developed in each participant assessed on magnetic resonance imaging (MRI) scans.
Time frame: Weeks 48 and 96
Number of Galdolinium (Gd)-Enhancing Lesions at Weeks 48 and 96
The number of Gd-enhancing lesions was assessed by using MRI scans.
Time frame: Weeks 48 and 96
Annualized Relapse Rate
A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. The relapse rate for an individual participant was calculated as the number of relapses for that participant divided by the number of participant-years followed. The ARR for each enrolment group was calculated as the total number of relapses experienced in the group divided by the total number of participant-years on the study. An unadjusted relapse rate is reported.
Time frame: Up to Week 96
Participants were enrolled at the investigative sites in Estonia, Tunisia, Turkey, Jordan and Taiwan from 19 March 2019 to 21 July 2022.
| Milestone | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo |
|---|---|---|---|
| Started | 2 | 6 | 3 |
| Completed | 2 | 3 | 2 |
| Not completed | 0 | 3 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Worsening of multiple sclerosis attack | 0 | 0 | 1 |
A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. Time to relapse is defined as from the first dose of the study drug to the day of relapse. Time to First Relapse is estimated by Kaplan Mayer method.
| Days | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo |
|---|---|---|---|
| Time to First Relapse | 413 (413 to 413) | NA (NA to NA) | 166.5 (113 to 220) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo |
|---|---|---|---|
| AEs | 2 | 6 | 3 |
| SAEs | 1 | 0 | 1 |
The number of new or newly enlarging T2 hyperintense lesions that developed in each participant assessed on magnetic resonance imaging (MRI) scans.
| number of lesions | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo |
|---|---|---|---|
| Week 48 | 0.5 (0 to 1) | 1.0 (0 to 3) | 3.3 (2 to 4) |
| Week 96 | 2.5 (0 to 5) | 1.3 (0 to 3) | 3.5 (2 to 5) |
The number of Gd-enhancing lesions was assessed by using MRI scans.
| number of lesions | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo |
|---|---|---|---|
| Week 48 | 0 (0 to 0) | 0 (0 to 0) | 1.5 (0 to 3) |
| Week 96 | 0 (0 to 0) | 0.25 (0 to 1) | 0.5 (0 to 1) |
A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. The relapse rate for an individual participant was calculated as the number of relapses for that participant divided by the number of participant-years followed. The ARR for each enrolment group was calculated as the total number of relapses experienced in the group divided by the total number of participant-years on the study. An unadjusted relapse rate is reported.
| relapses per participant year | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo |
|---|---|---|---|
| Annualized Relapse Rate | 0.26 | 0.00 | 0.46 |
Collected over Baseline up to Week 100. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dimethyl Fumarate 240 mg | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Peginterferon Beta-1a 125 µg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Placebo | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo |
|---|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 1/2 | 0/6 | 1/3 |
| Event | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 1/2 | 4/6 | 1/3 |
| Multiple sclerosis relapseNervous system disorders | 1/2 | 0/6 | 2/3 |
| Vaginal infectionInfections and infestations | 1/2 | 0/6 | 0/3 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/2 | 0/6 | 0/3 |
| ErythemaSkin and subcutaneous tissue disorders | 1/2 | 0/6 | 0/3 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/2 | 0/6 | 1/3 |
| Abdominal painGastrointestinal disorders | 0/2 | 2/6 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 0/2 | 0/6 | 1/3 |
| Gastrointestinal disorderGastrointestinal disorders | 0/2 | 0/6 | 1/3 |
| FatigueGeneral disorders | 0/2 | 1/6 | 1/3 |
Safety population included all participants who had received at least 1 dose of study treatment.
| Age, Continuous(years) | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo | Total |
|---|---|---|---|---|
| Mean | 15.5 ± 2.12 | 15.7 ± 1.51 | 15.7 ± 1.15 | 15.6 ± 1.36 |
| Sex: Female, Male(Participants) | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo | Total |
|---|---|---|---|---|
| Female | 1 | 5 | 2 | 8 |
| Male | 1 | 1 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 6 | 3 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dimethyl Fumarate 240 mg | Peginterferon Beta-1a 125 µg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 2 | 5 | 3 | 10 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Mar 2019 to primary completion in Jul 2022, 40 months.
Results were first posted in May 2023, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dimethyl Fumarate · Peginterferon beta-1a
Multiple Sclerosis, Relapsing-Remitting →